Document Detail

The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.
MedLine Citation:
PMID:  20945995     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking.
RESEARCH DESIGN AND METHODS: This was a retrospective single-centre study to assess the association between exposure to IFN for hepatitis C virus treatment and haematological side effects of DFP therapy in patients with thalassemia major and intermedia using a large database spanning 2001 – 2008. During observation time, a total of 66 patients, including 63 affected by thalassemia major and 3 by thalassemia intermedia, were treated with chelation DFP-based regimens. A subset of 25 patients was treated at least for 3 months also with IFN (6 were cotreated and 19 were pretreated).
RESULTS: Overall, the incidence of neutropenia and agranulocytosis was 9.83 and 1.14/100 patient/year, respectively. Receipt of IFN was significantly associated with increased risk of haematological complications of DFP therapy: among patients receiving IFN, 48 and 12% experienced at least one episode of neutropenia and agranulocytosis, respectively.
CONCLUSIONS: These results suggest that IFN therapy may increase the risk of complications of DFP-based iron chelation therapy in patients with thalassemia. Further research is needed to assess whether the association observed in this retrospective single-centre observational study is due to IFN or other factors.
Paolo Ricchi; Massimiliano Ammirabile; Silvia Costantini; Patrizia Cinque; Alfonso Galeota Lanza; Anna Spasiano; Tiziana Di Matola; Giovanni Di Costanzo; Leonilde Pagano; Luciano Prossomariti
Related Documents :
24153965 - Hospital readmission from hospice identifying causes and demographics.
20600025 - Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with ch...
8574465 - A phase ii trial of continuous-infusion recombinant interleukin-2 in patients with adva...
20542675 - Limited usefulness of quantiferon-tb gold in-tube for monitoring anti-tuberculosis ther...
8678445 - Palliation of carcinoma of the oesophagus with brachytherapy and the didcott dilator.
4066735 - Assessment of transcutaneous oxygen tension in ischaemic legs by means of using an elec...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  9     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-15     Completed Date:  2011-03-28     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  875-81     Citation Subset:  IM    
Dipartimento di oncoematologia, U.O.C. Centro delle Microcitemie A. Mastrobuoni, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Via A. Cardarelli 9, Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Agranulocytosis / chemically induced*
Antiviral Agents / therapeutic use*
Deferoxamine / therapeutic use
Drug Therapy, Combination
Hepatitis C, Chronic / drug therapy
Interferon-alpha / adverse effects,  therapeutic use*
Middle Aged
Neutropenia / chemically induced*
Polyethylene Glycols / adverse effects,  therapeutic use*
Pyridones / adverse effects*
Recombinant Proteins
Retrospective Studies
Siderophores / therapeutic use*
beta-Thalassemia / drug therapy
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/Pyridones; 0/Recombinant Proteins; 0/Siderophores; 0/peginterferon alfa-2b; 2BTY8KH53L/deferiprone; 70-51-9/Deferoxamine; 99210-65-8/interferon alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head...
Next Document:  Diagnosis and cause of death in a neonatal intensive care unit - How important is autopsy?